Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
|Articles|April 26, 2016
World Excipients Market to Reach $6.4 Billion by 2020, Says Report
April 26, 2016.
Advertisement
The world pharmaceuticals excipients market will reach $6.4 billion by 2020, according to a report by Allied Market Research.
Among other findings, the study states that:
- Binders generated the highest revenue accounting for about two-seventh of the overall market revenue in 2015.
- Asia-Pacific is anticipated to be the fastest growing pharmaceutical excipients market, for both organic and inorganic chemicals, in terms of volume and revenue during 2015 and 2020.
- North America accounted for about one third of the overall market revenue in 2015 owing to the presence of large number of pharmaceutical companies.
For more information, visit
Advertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Advertisement
Advertisement
Trending on PharmExec
1
ANI Pharmaceuticals to Acquire Egetis Therapeutics, Egetis Sells Priority Review Voucher for $190 Million
2
Why Leronlimab Isn’t Just Another Repurposed Drug: Q&A with Dr. Jay Lalezari
3
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
4
What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?
5